This study focused on breast cancer (BC) and explored the relationship between the expression of human epidermal growth factor receptor-2 (HER-2) and tumor-infiltrating lymphocyte (TIL) and its clinicopathological features. Here, ERBB2 is linked to breast carcinoma.